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Abstract: Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a cardioprotective phytochemical occurring
in many plant products. In this study, a new series of imine congeners of resveratrol has been
synthesized in which the imine moiety replaced the double bond in the structure of resveratrol.
In addition, the in vitro antiplatelet activity of these resveratrol derivatives has been evaluated
against adenosine diphosphate (ADP), arachidonic acid (AA), and collagen as platelet aggregation
inducers. In general, the synthesized compounds were active as antiplatelet agents, and, therefore,
the imine functional group may be considered as an effective replacement for a double bond in
resveratrol for developing new and promising antiplatelet drugs.
Keywords: stilbenes; cardioprotection; antiplatelet drugs; polyphenols
1. Introduction
Cardiovascular diseases (CVDs) are recognized as the first global cause of death. It has been
reported by the World Health Organization (WHO) that 17.7 million people died from CVDs in
2015 [1,2]. Platelet aggregation plays an essential role in the process of blood clotting and CVDs.
However, many antiplatelet drugs such as aspirin and clopidogrel, which are available in clinics,
are associated with some side effects such as bleeding and drug resistance that limit their usage [3,4].
Therefore, the search for new antiplatelet agents with fewer side effects and higher efficacy is among
the priorities of medicinal chemists.
Natural products with various chemical structures have an important role in drug discovery
and development [5–9]. Although chemical diversity of the natural products is pivotal in finding
useful lead compounds, usually chemical modifications are needed to improve their potency and
physicochemical properties [10–12]. Resveratrol (3,5,4′-trihydroxy-trans-stilbene) (1) (Figure 1) is
one of these lead compounds. This stilbene is found in many natural sources such as grapes,
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apples, and berries [13–15]. Various biological activities of resveratrol have been reported such
as anticancer, anti-inflammatory, antioxidant, and antiplatelet [13,16,17]. Orsini et al. synthesized and
evaluated the antiplatelet aggregation activity of resveratrol 3-O-β-D-glucopyranoside and related
hyroxystilbenes [18]. Dutra et al. synthesized new resveratrol and resveratrol-furoxan hybrids as
antiplatelet and antithrombotic agents [19].
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Figure 1. Design of im ne resverat ol derivatives.
A literature review revealed that C=N moiety is present in many structures with
antiplatelet activity. Tehrani et al. synthesized a series of Schiff bases derived from
2-hydrazinyl-1,3,4-thiadiazole with high antiplatelet activity [20]. Akhlaghi et al. reported
3-(arylimino)indolin-2-one and 1-(aryl)-3-(phenylimino)indolin-2-one derivatives as antiplatelet
agents [21]. Among their synthesized derivatives, compound (2) exhibited high antiplatelet
activity against arachidonic acid (AA) as a platelet aggregation inducer (IC50 = 3.4 µM) [21].
Furthermore, antiplatelet activity of N′-benzylidene-carbohydrazide-1H-pyrazolo[3,4-b]pyridine
derivatives have been reported [22]. A variety of indole hydrazone derivatives such as
indole N-acylhydrazones [23,24], indole-3-carboxaldehyde phenylhydrazones [25], N-1 substituted
indolehydrazones [26], indole-3-carbaldehyde, and indole-2-carbaldehayde hydrazones [27] have been
previously synthesized in our research group. Some of these reported derivatives exhibited remarkable
antiplatelet activity.
Therefore, the present research was aimed at the synthesis of a new series of imine congeners
of resveratrol in which the imine moiety replaced the double bond in the structure of resveratrol
(Figure 1) [28], and the evaluation of their in vitro antiplatelet activity against adenosine diphosphate
(ADP), arachidonic acid (AA), and collagen as platelet aggregation inducers.
2. Results and Discussion
2.1. Chemistry
The designed compounds were synthesized by the reaction of different aniline derivatives with
appropriate aldehydes in water as a green solvent without any catalyst (Figure 2). The synthesized
derivatives (3a–3r) were obtained with high yields (>89%). Structure of the synthesized compounds
was characterized by LC-MS 1H-NMR and 13C-NMR. The 1H-NMR spectra of the synthesized
compounds exhibited a singlet peak for the CH=N proton between 8.51 and 8.96 ppm.
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2.2. Anti-Platelet Activity
The anti-platelet activity of the synthesized derivatives against ADP, AA, and collagen as platelet
aggregation inducers were evaluated, according to the Born method [29,30]. The obtained data are
presented in Table 1.
Table 1. Anti-platelet activity of the synthesized derivatives. Adenosine diphosphate (ADP),
arachidonic acid (AA), and collagen were used as a platelet aggregation inducer at a final concentration
of 5 µM, 1.35 µM, and 2.5 µg·mL−1, respectively. The results are expressed as the mean ± standard
error of mean (SEM) from three independent experiments.
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Compound R R′ AA
a
Inhibition (%)
AA
(IC50 µM)
ADP a
Inhibition (%)
Collagen a
Inhibition (%)
3a 4-OCH3 - 74.7 ± 2.5 301.0 ± 8.7 43.2 ± 3.3 15.9 ± 1.5
3b 3-OCH3, 4-OH - 100 180.2 ± 5.4 52.1 ± 2.2 39.0 ± 8.8
3c 2-OH 4′-OCH3 100 86.1 ± 6.6 30.2 ± 5.3 46.8 4.3
3d 4-OCH3 4′-OCH3 100 155.5 ± 4.3 41.4 ± 6.4 29.1 ± 1.9
3e 3,4-dimethoxy 4′-OCH3 100 73.6 ± 3.4 63.2 ± 3.1 80.7 ± 1.4
3f 4-CH3 4′-OCH3 100 143.3 ± 6.2 33.6 ± 1.4 60.0 4.1
3g 3-OCH3, 4-OH 4′-OCH3 94.9 ± 0.7 179.2 ± 7.1 34.4 ± 5.6 41.0 ± 6.6
3h 3-OCH3 4′-OH 100 69.1 ± 5.4 77.4 ± 1.9 73.1 ± 2.1
3i 2-OH 4′-OH 100 29.9 ± 1.1 36.3 ± 3.9 70.8 ± 1.3
3j 4-OCH3 4′-OH 100 68.3 ± 1.4 44.1 ± 3.6 67.2 ± 3.2
3k 4-CH3 4′-OH 100 65.4 ± 3.4 45.8 ± 3.3 59.03 ± 6.2
3l 3,4-dimethoxy 4′-OH 93.7 ± 5.6 65.3 ± 2.0 53.5 ± 2.7 67.8 ± 3.5
3m 3,4,5-trimethoxy 4′-OH 88.0 ± 3.1 65.2 ± 3.4 84.6 ± 1.1 93.4 0.9
3n 3-OH 4′-OH 100 62.3 ± 7.1 33.4 ± 3.5 80.5 ± 1.4
3o 2-OCH3 4′-OH 92.4 ± 2.1 130.7 ± 5.1 43.8 ± 1.6 74.9 ± 3.4
3p 2-OH 2′-OH 95.1 ± 3.0 65.5 ± 4.3 4 .1 ± 3.7 70. 2.5
3q 3-OH 2′-OH 100 30.7 ± 1.2 38.4 ± 3.9 36.1 ± 3.5
3r 4-CH3 2′-OH 100 19.8 ± 1.1 39.8 ± 3.2 63.5 ± 1.3
Indomethacin 1.67 ± .67 42.0 ± 1.1
Acetyl salicylic
acid (ASA) 0.24 ± 0.05 21.0 ± 0.6
a Inhibition of platelet aggregation was assessed at 1 mM concentration.
2.3. Structure Activity Relationship
The data reported in Table 1 show that all the compounds (3a–3r) at the concentration of 1 mM
inhibited platelet aggregation induced by ADP, AA, and collagen. The inhibition range for ADP and
collagen were 30%–84.6% and 15.9%–93.4%, respectively. When AA was used as a platelet aggregation
inducer, the inhibition was increased and ranged from 74.7% to 100%.
Compound 3m with three-methoxy group on ring A inhibited platelet aggregation induced by all
the three platelet inducers above 85%.
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Since all compounds at concentration of 1 mM were able to completely inhibit platelet aggregation
induced by AA, the IC50 values for these compounds were calculated (Table 1).
As shown in Table 1, all the compounds with hydroxyl substituent on the B ring show high
activity (IC50 < 69.1 µM) except 3o. The results demonstrated that all the compounds with Schiff base
and phenolic hydroxyl groups at the ortho position of ring A or B show IC50 values ranging between
19.8 µM and 30.7 µM except for 3c and 3p. Compounds 3i and 3q exhibited satisfactory activity with
IC50 values of 29.9 µM and 30.7 µM, respectively. Compound 3r with IC50 value of 19.8 µM was the
most active compound.
3. Materials and Methods
3.1. General Procedure for the Preparation of 3a–3r
The mixture of aromatic amine (1 mmol) and aldehyde (1 mmol) in water was stirred at room
temperature. After completion of the reaction indicated by TLC (thin-layer chromatography), the
obtained precipitate was filtered off and washed with water. The obtained precipitate was recrystallized
from the appropriate solvent.
(E)-1-(4-Methoxyphenyl)-N-phenylmethanimine (3a). Yield 95%; m.p. 48–50 ◦C (m.p. 49–50 ◦C [31]).
ESI-MS m/z: 212 [M + H]+. Anal. Calcd for C14H13NO: C 79.59, H 6.20, N 6.63, found C 79.57, H 6.21,
N 6.64.
(E)-2-Methoxy-4-[(phenylimino)methyl]phenol (3b). Yield 89%. m.p. 159–162 ◦C (m.p. 158–160 ◦C [32]).
ESI-MS m/z: 228 [M + H]+; Anal. Calcd for C14H13NO2: C 73.99, H 5.77, N 6.16, found C 73.97, H 5.76,
N 6.15.
(E)-2-{[(4-Methoxyphenyl)imino]methyl}phenol (3c). Yield 94%. m.p. 76–77 ◦C; 1H-NMR (400 MHz,
DMSO-d6) δ 13.32 (s, 1H, OH), 8.94 (s, 1H, HC=N), 7.61 (m, 1H, Ar-H), 7.42 (m, 3H, Ar-H), 6.96
(m, 4H, Ar-H), 3.79 (s, 3H, OCH3). 13C-NMR (100 MHz, DMSO-d6) δ 161.72, 160.62, 158.99, 141.19,
133.25, 132.80, 123.09, 119.85, 119.53, 116.97, 115.13, 55.86; ESI-MS m/z: 228 [M + H]+. Anal. Calcd for
C14H13NO2: C 73.99, H 5.77, N 6.16, found C 73.95, H 5.76, N 6.17.
(E)-N,1-bis(4-Methoxyphenyl)methanimine (3d). Yield 89%. m.p. 154–155 ◦C (m.p. 154 ◦C [33]). ESI-MS
m/z: 242 [M + H]+. Anal. Calcd for C15H15NO2: C 74.67, H 6.27, N 5.81, found C 74.68, H 6.28, N 5.79.
(E)-1-(3,4-Dimethoxyphenyl)-N-(4-methoxyphenyl)methanimine (3e). Yield 85%. m.p. 126–128 ◦C. 1H-NMR
(400 MHz, DMSO-d6) δ 8.52 (s, 1H, HC=N), 6.96–7.54 (m, 7H, Ar-H), 3.77–3.83 (m, 9H, OCH3); 13C-NMR
(100 MHz, DMSO-d6) δ 158.46, 158.05, 151.97, 149.45, 144.89, 129.77, 124.08, 122.66, 115.46, 114.95,
114.85, 111.74, 109.68, 56.07, 55.88, 55.73. ESI-MS m/z: 272 [M + H]+. Anal. Calcd for C16H17NO3:
C 70.83, H 6.32, N 5.16, found C 70.81, H 6.31, N 5.17.
(E)-N-(4-Methoxyphenyl)-1-(p-tolyl)methanimine (3f). Yield 96%. m.p. 87–88 ◦C. 1H-NMR (400 MHz,
DMSO-d6) δ 8.59 (s, 1H, HC=N), 7.70-7.81 (m, 2H, Ar-H), 7.31-7.42 (m, 4H, Ar-H), 6.98 (m, 2H, Ar-H),
3.78 (s, 3H, OCH3), 2.38 (s, 3H, OCH3). 13C-NMR (100 MHz, DMSO-d6) δ 158.2, 157.8, 144.2, 141.0,
133.8, 129.85, 128.88, 122.79, 114.87, 55.76, 21.1. ESI-MS m/z: 226 [M + H]+. Anal. Calcd for C15H15NO:
C 79.97, H 6.71, N 6.22, found C 79.95, H 6.70, N 6.23.
(E)-2-Methoxy-4-{[(4-methoxyphenyl)imino]methyl}phenol (3g). Yield 94%. m.p. 154–155 ◦C (m.p.
154 ◦C [34]). ESI-MS m/z: 258 [M + H]+. Anal. Calcd for C15H15NO3: C 70.02, H 5.88, N 5.44,
found C 70.01, H 5.89, N 5.43.
(E)-4-[(3-Methoxybenzylidene)amino]phenol (3h). Yield 94%. m.p. 165–167 ◦C (m.p. 167 ◦C [35]). ESI-MS
m/z: 228 [M + H]+. Anal. Calcd for C14H13NO2: C 73.99, H 5.77, N 6.16, found C 73.97, H 5.76, N 6.15.
(E)-2-{[(4-Hydroxyphenyl)imino]methyl}phenol (3i). Yield 98%. m.p. 140–143 ◦C. 1H-NMR (400 MHz,
DMSO-d6) δ 13.44 (s, 1H, OH), 9.72 (s, 1H, OH), 8.94 (s, 1H, HC=N), 7.58 (m, 1H, Ar-H), 7.31–7.37 (m,
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3H, Ar-H), 6.84–6.95 (m, 4H, Ar-H). 13C-NMR (100 MHz, DMSO-d6) δ 160.67, 160.60, 157.41, 139.65,
133.00, 132.67, 123.12, 119.89, 119.46, 116.92, 116.43, 116.01, 115.85. ESI-MS m/z: 214 [M + H]+. Anal.
Calcd for C13H11NO2: C 73.23, H 5.20, N 6.57, found C 73.21, H 5.21, N 6.56.
(E)-4-[(4-Methoxybenzylidene)amino]phenol (3j). Yield 95%. m.p. 187–188 ◦C (m.p. 189 ◦C [36]). ESI-MS
m/z: 228 [M + H]+. Anal. Calcd for C14H13NO2: C 73.99, H 5.77, N 6.16, found C 74.20, H 5.77, N 6.15.
(E)-4-[(4-Methylbenzylidene)amino]phenol (3k). Yield 94%. m.p. 152–153 ◦C; 1H-NMR (400 MHz,
DMSO-d6) δ 9.51 (s, 1H, OH), 8.55 (s, 1H, HC=N), 7.78 (m, 2H, Ar-H), 7.18–7.30 (m, 4H, Ar-H), 6.80 (m,
2H, Ar-H), 2.36 (s, 3H, CH3); 13C-NMR (100 MHz, DMSO-d6) δ 157.51, 156.57, 143.19, 141.24, 134.36,
129.82, 128.73, 122.86, 116.15, 21.59; ESI-MS m/z: 212 [M + H]+. Anal. Calcd for C14H13NO: C 79.59,
H 6.20, N 6.63, found C 79.45, H 6.19, N 6.62.
(E)-4-[(3,4-Dimethoxybenzylidene)amino]phenol (3l). Yield 92%. m.p. 155–156 ◦C (m.p. 155 ◦C [37]).
ESI-MS m/z: 258 [M + H]+. Anal. Calcd for C15H15NO3: C 70.02, H 5.88, N 5.44, found C 70.10, H 5.87,
N 5.45.
(E)-4-[(3,4,5-Trimethoxybenzylidene)amino]phenol (3m). Yield 96%. m.p. 140–142 ◦C. 1H-NMR (400 MHz,
DMSO-d6) δ 9.53 (s, 1H, OH), 8.51 (s, 1H, HC=N), 7.18–7.23 (m, 4H, Ar-H), 6.81 (m, 2H, Ar-H), 3.85 (s,
6H, OCH3), 3.73 (s, 3H, OCH3). 13C-NMR (100 MHz, DMSO-d6) δ 157.42, 156.60, 153.58, 143.06, 140.31,
132.44, 122.85, 116.19, 115.87, 107.19, 105.88, 60.61, 56.50, 56.36; ESI-MS m/z: 288 [M + H]+. Anal. Calcd
for C16H17NO4: C 66.89, H 5.96, N 4.88, found C 66.84, H 5.95, N 4.88.
(E)-3-{[(4-Hydroxyphenyl)imino]methyl}phenol (3n). Yield 94%. m.p. 191–193 ◦C. 1H-NMR (400 MHz,
DMSO-d6) δ 9.69 (s, 1H, OH), 9.55 (s, 1H, OH), 8.51 (s, 1H, HC=N), 7.19–7.37 (m, 5H, Ar-H), 6.83–6.91
(m, 3H, Ar-H). 13C-NMR (100 MHz, DMSO-d6) δ 158.10, 157.66, 156.70, 143.04, 138.29, 130.23, 122.95,
120.44, 118.64, 116.19, 115.90, 114.35; ESI-MS m/z: 214 [M + H]+. Anal. Calcd for C13H11NO2: C 73.23,
H 5.20, N 6.57, found C 73.21, H 5.21, N 6.58.
(E)-4-[(2-Methoxybenzylidene)amino]phenol (3o). Yield 92%. m.p. 168–169 ◦C (m.p. 168 ◦C [35]). ESI-MS
m/z: 228 [M + H]+. Anal. Calcd for C14H13NO2: C 73.99, H 5.77, N 6.16, found C 73.94, H 5.78, N 6.15.
(E)-2-[(2-Hydroxybenzylidene)amino]phenol (3p). Yield 98%. m.p. 141–143 ◦C. 1H-NMR (400 MHz,
DMSO-d6) δ 13.81 (s, 1H, OH), 9.77 (s, 1H, OH), 8.96 (s, 1H, HC=N), 7.13–7.61 (m, 4H, Ar-H), 6.89–6.95
(m, 4H, Ar-H). 13C-NMR (100 MHz, DMSO-d6) δ 162.13, 161.20, 151.56, 135.40, 133.31, 132.78, 128.53,
120.09, 120.04, 119.96, 119.21, 117.16, 116.98. ESI-MS m/z: 214 [M + H]+. Anal. Calcd for C13H11NO2:
C 73.23, H 5.20, N 6.57, found C 73.24, H 5.19, N 6.56.
(E)-2-[(3-Hydroxybenzylidene)amino]phenol (3q). Yield 99%. m.p. 122–124 ◦C (m.p. 122.5–123.5 ◦C [38]).
ESI-MS m/z: 214 [M + H]+. Anal. Calcd for C13H11NO2: C 73.23, H 5.20, N 6.57, found C 73.24, H 5.19,
N 6.55.
(E)-2-[(4-Methylbenzylidene)amino]phenol (3r). Yield 98%. m.p. 107–108 ◦C (m.p. 108.5 ◦C [39]). ESI-MS
m/z: 212 [M + H]+. Anal. Calcd for C14H13NO: C 79.59, H 6.20, N 6.63, found C 79.58, H 6.19, N 6.64.
3.2. Anti-Platelet Assay
The anti-platelet aggregation activity of the synthesized compounds was evaluated on an
APACT 4004 aggregometer (LABiTec, Ahrensburg, Germany), according to the method described
before [29,40,41]. Compounds (3a–3r) were added to platelet-rich plasma (PRP) and were incubated for
5 min at 37 ◦C. Adenosine diphosphate (ADP), arachidonic acid, and collagen were added separately as
platelet aggregation inducers at a final concentration of 5 µM, 1.35 µM, and 2.5 µg·mL−1, respectively.
The aggregation procedure was monitored for 5 min. Compounds were screened at a concentration
of 1 mM in DMSO. The IC50 values against AA were determined for the synthesized compounds.
Each experiment was carried out in triplicate and the results are shown as a mean ± standard error of
mean (SEM).
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4. Conclusions
In the present study, a series of resveratrol derivatives was synthesized and their antiplatelet
activity was evaluated against ADP, AA, and collagen as platelet aggregation inducers. Compound 3r
was the most active agent against AA and, therefore, possesses the potential to be considered a
lead compound for future studies and further investigations. Lastly, the imine functional group
may be qualified as an effective replacement for the double bond in resveratrol for anti-platelet
aggregation pharmacophore.
Supplementary Materials: The following are available online http://www.mdpi.com/1422-8599/2019/1/
M1039/s1, Figure S1: Qualitative data analysis report.
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